The Point of Care Diagnostics/Testing Market Size was valued at USD 44.5 billion in 2023 and is expected to reach USD 70.92 billion by 2031, and grow at a CAGR of 6% over the forecast period 2024-2031.
Point of care diagnostics/testing is a type of health analysis that is performed near the patient and does not require a laboratory environment. Point of care (POC) testing is also known as near-patient testing, bedside testing, mobile testing, remote testing, and rapid diagnosis. The approach is used to diagnose infectious diseases in areas with little healthcare infrastructure. A point-of-care (POC) diagnostic device collects specific clinical data from patients in clinical and resource-limited scenarios. Traditional clinical diagnostic techniques demand high-end and costly tools, a professional technician for operation and result interpretation, and more time, all of which depletes and costs money.
Get more information on Point Of Care Diagnostics/Testing Market - Request Sample Report
Despite substantial improvements in medical facilities in various regions' healthcare systems, the use of POC diagnostic equipment is still in its infancy.
KEY DRIVERS:
Globally, the number of chronic disease cases is increasing.
There is an increasing demand for AI-integrated proof-of-concepts for real-time diagnostics.
RESTRAINTS:
The multi-layered rules imposed by international governing bodies such as the FDA and CLIA are limiting the market expansion of POC producers and creating a regulatory barrier in the promotion and sale of their goods.
Healthcare device producers must submit performance data for their products, detailing the benefits and drawbacks of the product on the persons who have been tested.
CHALLENGES:
The challenge that manufacturers face is deploying their products in accordance with regional authorities.
The pandemic epidemic halted operations in all sectors around the world. During the initial period of the lockdown, the healthcare industry was particularly heavily hit. Medical supplies were stacked up in huge quantities, and the number of manufactured goods increased as the supply chain within and across borders was severely disrupted by the adoption of the safety requirements. However, as the number of impacted patients decreased, regulatory authorities permitted restricted mobility and manufacturing of vital products. The loosening of rules boosted demand for healthcare items that serve the point-of-care diagnostics/testing sector.
During the pandemic, market participants invested much in the development of fast testing for COVID-19 diagnosis. According to WHO, the industry participants will collaborate in September 2020 to develop 120 million economic antigen-based quick diagnostic POC tests for developing countries. The Bill & Melinda Gates Foundation (US), SD BioSensor Inc. (South Korea), and Abbott Laboratories (US) agreed to offer the POC test products for a maximum of USD 5. The Global Fund provided USD 50 million to help low- and middle-income countries (LMICs) purchase the diagnostic test. Furthermore, the FDA authorised the POC antibody test for COVID-19 in September 2020, which will allow patients to understand their health condition and determine whether the virus has infected them or not.
Furthermore, regulatory agencies modified their point-of-care and quick testing criteria for SARS-CoV-2. These enabling factors boosted market expansion and are likely to increase during the forecast period. Glucose Testing It is a device that measures the concentration of glucose in the blood using a lancet, metre, or other device. Cardiometabolic Testing It is a sort of monitoring device that measures the risk associated with cardiovascular functions such as blood pressure, blood gas, blood fat, LDL (low-density lipoprotein) levels, and so on.
Testing for Infectious Diseases It is a gadget that identifies diseases caused by organisms like viruses, bacteria, and fungi. Coagulation Testing It is a gadget that evaluates blood clotting capacity. It will provide valuable information to clinicians on the proper deployment of clotting factor in the bleeding area. Fertility and pregnancy testing It is a device that assesses both men and women's potential to conceive naturally as well as the existence of any sexually transmitted infections.
Hematology Examination These machines do blood tests to assess total blood count, protein levels, infection, inflammation, blood-clotting disorders, anaemia, and leukaemia. Cancer/Tumor Marker Analysis It is a gadget that detects tumour markers in blood, tissue, urine, and other bodily fluids. The device monitors the protein and other chemicals produced in response to tumour cells. Urinalysis Examination This gadget detects kidney abnormalities, diabetes levels, liver difficulties, and other metabolic functions, as well as diagnoses urinary tract infections. Cholesterol It is a gadget that detects high-density and low-density proteins as well as specific lipids in the blood.
Abuse Examination It is a non-medical equipment that detects illegal chemicals in urine, saliva, blood, hair, and perspiration. Hospitals and Clinics Hospitals and Clinics are organisations that provide medical and surgical care to the injured. Diagnostic Facilities It is a facility that provides diagnostic services to the general public and medical practitioners. Self-Testing at Home It is professional caregiver healthcare help provided to patients in their homes for health services. OTC Testing Supplies It is a test that does not require a prescription and is not limited to specific healthcare settings.
Prescription-only testing solutions It is a type of test that is performed depending on a doctor's prescription. Immunoassays It is a platform for measuring specific proteins and auxiliary chemicals based on their antigen and antibody characteristics. Molecular Testing It is a platform for identifying disease through the use of molecules such as DNA, RNA, tissue, fluid, and proteins. Dipsticks It is a chemically integrated sensitive strip of paper that detects glucose, protein, and other urinary components.
by End User
Hospitals & Clinics
Diagnostic Centers
Homecare/Self Testing
Others
by Mode of Purchase
OTC Testing Products
Prescription-based testing products
by Platform
Immunoassays
Dipsticks
Others
by Product
Cardiometabolic Monitoring
Infectious Disease Testing
Coagulation Monitoring
Pregnancy & Fertility Testing
Hematology Testing
Cancer/Tumor Marker Testing
Urinalysis Testing
Cholesterol
Drugs-of-Abuse Testing
Others
North America held the highest share of the point of care diagnostics/testing market in 2021, owing to an increasing number of market players across the region, acquisitions of industry players by healthcare behemoths, and favourable government regulations. Healthcare product providers are merging and acquiring current market participants in order to expand their product availability across the region. For business expansion, market participants are implementing business strategies such as the launch of new products, R&D activities, and collaborative product creation.
Due to restricted healthcare staff availability, diverse manufacturing facilities, changing demographics, and increasing consumer healthcare expectations, the Asia-Pacific point of care diagnostics/testing market is expected to be the fastest-growing regional market. Furthermore, comforting government rules, significant funding from industry participants, and technologically advanced product innovation are all elements boosting the point of care diagnostics/testing market.
Need any customization research on Point of Care Diagnostics/Testing Market - Enquiry Now
REGIONAL COVEREGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Major players are Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., PTS Diagnostics, Nova Biomedical, QuidelCorporation, Abbott Laboratories, Siemens Healthineers GmbH, Chembio Diagnostics, Inc., Becton, Dickinson and Company, Danaher Corporation and Other Players.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 44.5 Billion |
| Market Size by 2031 | US$ 70.92 Billion |
| CAGR | CAGR of 6% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • by Mode of Purchase (OTC, Prescription-based) • by Platform (Immunoassays, Molecular Diagnostics, Dipsticks) • by Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Hematology Testing, Cancer/Tumor Marker Testing, Urinalysis Testing, Cholesterol, Drugs-of-Abuse Testing) • by End User (Hospitals & Clinics, Diagnostic Centers, Homecare/Self Testing) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., PTS Diagnostics, Nova Biomedical, QuidelCorporation, Abbott Laboratories, Siemens Healthineers GmbH, Chembio Diagnostics, Inc., Becton, Dickinson and Company, Danaher Corporation. |
| Key Drivers | • Globally, the number of chronic disease cases is increasing. |
| RESTRAINTS | • Healthcare device producers must submit performance data for their products, detailing the benefits and drawbacks of the product on the persons who have been tested. |
Ans: The Point of Care Diagnostics/Testing Market Size was valued at USD 23.99 billion in 2022.
Ans: The Point of Care Diagnostics/Testing market is to grow at a CAGR of 11.9% over the forecast period 2023-2030.
Ans: Point of care diagnostics/testing is a type of health analysis that is performed near the patient and does not require a laboratory environment. Point of care (POC) testing is also known as near-patient testing, bedside testing, mobile testing, remote testing, and rapid diagnosis.
Globally, the number of chronic disease cases is increasing.
There is an increasing demand for AI-integrated proofs-of-concept for real-time diagnostics.
Ans: The challenge that manufacturers face is deploying their products in accordance with regional authorities.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Point of Care Diagnostics/Testing Market, by End User
8.1 Hospitals & Clinics
8.2 Diagnostic Centers
8.3 Homecare/Self Testing
8.4 Others
9. Point of Care Diagnostics/Testing Market, by Mode of Purchase
9.1 OTC Testing Products
9.2 Prescription-based testing products
10. Point of Care Diagnostics/Testing Market, by Platform
10.1 Immunoassays
10.2 Molecular Diagnostics
10.3 Dipsticks
10.4 Others
11. Point of Care Diagnostics/Testing Market, by Product
11.1 Glucose Monitoring
11.2 Cardiometabolic Monitoring
11.3 Infectious Disease Testing
11.4 Coagulation Monitoring
11.5 Pregnancy & Fertility Testing
11.6 Hematology Testing
11.7 Cancer/Tumor Marker Testing
11.8 Urinalysis Testing
11.9 Cholesterol
11.10 Drugs-of-Abuse Testing
11.11 Others
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 USA
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4 Asia-Pacific
12.4.1 Japan
12.4.2 South Korea
12.4.3 China
12.4.4 India
12.4.5 Australia
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.1 Israel
12.5.2 UAE
12.5.3 South Africa
12.5.4 Rest
12.6 Latin America
12.6.1 Brazil
12.6.2 Argentina
12.6.3 Rest of Latin America
13. Company Profiles
13.1 Hoffmann-La Roche Ltd
13.1.1 Financial
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 Johnson & Johnson Services, Inc.
13.3 PTS Diagnostics
13.4 Nova Biomedical
13.5 QuidelCorporation
13.6 Abbott Laboratories
13.7 Siemens Healthineers GmbH
13.8 Chembio Diagnostics, Inc.
13.9 Becton, Dickinson, and Company
13.10 Danaher Corporation
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share Analysis
14.3 Recent Developments
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The eHealth Market Size was valued at USD 346.86 billion in 2023, and will reach to USD 1330.55 billion by 2031 and grow at a CAGR of 18.3% by 2024-2031.
The Digital Clinical Trials Market was valued at USD 8.70 Bn in 2023 and is expected to reach at $13.86 Bn in 2031 and grow at a CAGR of 6 % by 2024-2031.
The Veterinary Vaccine Adjuvants Market size was valued at USD 9.18 billion in 2023 and is estimated to reach USD 15.24 billion by 2032 with a growing CAGR of 5.8% from 2024 to 2032.
The global dental regeneration market, valued at USD 5.03 Billion in 2023, is projected to reach USD 8.49 Billion by 2032, growing at a compound annual growth rate (CAGR) of 6.28% during the forecast period.
The Medication Management Market Size was valued at USD 7.08 Billion in 2023 and is expected to reach USD 13.37 Billion by 2032 and grow at a CAGR of 7.66% over the forecast period 2024-2032.
The Hospital Capacity Management Solutions Market Size was valued at USD 4.17 billion in 2023 and expected to reach USD 14.85 billion by 2031 and grow at a CAGR of 17.2% over the forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
